MannKind Discontinues Lung Trial, Hopes for Alternative

episode

Business News Today | 2 Min News | The Daily News Now! not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

More from Business News Today | 2 Min News | The Daily News Now!

Japanese Capsule Hotels: Budget Solution for London Hybrid Workers 1 min · 20 Dec 2025

Russia's War Economy: Sustainable or Unsustainable? 2 min · 20 Dec 2025

All episodes from Business News Today | 2 Min News | The Daily News Now! →

Report any issue

Source

Recorded10 Nov 2025

Publisherfeeds.acast.com ↗

Handlerec:2198479

Show notes

MannKind Corporations stock plummeted by four percent after halting a phase three clinical trial for a nebulized clofazimine treatment for nontuberculous mycobacterial lung disease. The treatment, MNKD-one hundred one, failed to demonstrate sufficient effectiveness. Despite this setback, MannKind remains optimistic about a dry powder version, MNKD-one hundred two, and held a conference call to discuss the developments with investors and express gratitude to those involved in the ICoN-one study.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.